Pharmaceutical company GlaxoSmithKline has temporarily discontinued two types of Excedrin products as a precautionary measure.
GlaxoSmithKline suspended production and distribution of its Excedrin Extra Strength and Excedrin Migraine products as a precaution. The company found inconsistencies in its production of the products.
In a statement, the pharma firm said: "Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs, and Excedrin Migraine Caplets and Geltabs."
While GlaxoSmithKline does not believe the products pose a safety risk to consumers, it has voluntarily suspended the Excedrin products as a precaution.
The statement continued: "We are working hard to resolve the issue as quickly as possible, but at this point in time cannot confirm a definite date as to when supply will resume. Other Excedrin products are available along with other pain-relieving drugs, but dosages may differ. Consumers should consult their pharmacist for the most suitable alternative product."
The company called it a short term issue and expects production to resume soon.
While other pain medicines from the company as well as generic drugs are still available, they may be in different dosage so the drug company advises consumers to consult their pharmacists for alternatives.
Ashleigh Eldred, who discovered that her preferred pain medicine wasn't available, said: "I've been suffering for about 10 years. I've gone to the doctors. I've tried prescription medicines. I had Botox. I've tried medical marijuana and I still end up going back to Excedrin."
The production issue comes as GSK is in the midst of integrating its consumer health operations with those of Pfizer. Both companies initially wanted to divest their own consumer health businesses but, in December 2018, struck a deal to merge them in a joint venture that they intend to spin off, although they are yet to settle the timing.
